

Amendments to the Claims:

The following amendments replace all prior claims and amendments in this case.

- 1-11. (canceled)
12. (currently amended) An antibody which specifically binds to a polypeptide ~~according to claim 9~~ having at least 80% amino acid sequence identity to (a) a polypeptide of SEQ ID NO:172; or (b) a polypeptide encoded by the full length coding region of the nucleotide sequence of SEQ ID NO:171.
13. (previously presented) The antibody of claim 12, wherein said antibody is a monoclonal antibody, a humanized antibody or a single-chain antibody.
14. (currently amended) A composition of matter comprising ~~(a) a polypeptide of claim 10, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an antibody that binds to said polypeptide~~ the antibody of Claim 12, in combination with a carrier.
15. (previously presented) The composition of matter of claim 14, wherein said carrier is a pharmaceutically acceptable carrier.
16. (currently amended) The composition of matter of claim 14 comprising a therapeutically effective amount of ~~(a), (b), (c) or (d)~~ the antibody of Claim 12.
17. (currently amended) An article of manufacture, comprising: a container; a label on said container; and a composition of matter comprising ~~(a) a polypeptide of claim 9, (b) an agonist of said polypeptide, (c) an antagonist of said polypeptide, or (d) an antibody that binds to said polypeptide~~ the antibody of Claim 12, contained within said container, wherein label on said container indicates that said composition of matter can be used for treating an immune related discase.
- 18-28. (canceled)